In murine melanoma models, the combination of zVAD-fmk with multimodal therapies has been shown to significantly reduce tumor growth, decrease regulatory T cell infiltration, and promote the recruitment of CD8+ T cells along with enhanced IFNγ expression. This evidence concerns the gene CD8A and neoplasm.